Citation Impact
1 from Science/Nature 57 standout
Citing Papers
PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment
2024 Standout
Tumor biomarkers for diagnosis, prognosis and targeted therapy
2024 Standout
Works of Ching Hsu being referenced
A randomized, placebo‐controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild‐type KRAS who have received first‐line systemic therapy
2016
A randomized, placebo-controlled, phase I/II study of tivantinib (ARQ 197) in combination with cetuximab and irinotecan in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (CRC) who had received previous front-line systemic therapy.
2013
Author Peers
| Author | Oncology | Molecular Biology | PRM | Physiology | Neurology | Last Decade | Papers | Cites |
|---|---|---|---|---|---|---|---|---|
| Ching Hsu | 105 | 76 | 36 | 128 | 84 | 22 | 345 | |
| J. Proboste | 6 | 530 | ||||||
| Li Xu | 8 | 52 | 8 | 8 | 200 | |||
| Matthew Davenport | 1 | 121 | 1 | 2 | 12 | 688 | ||
| Mario Ndreko | 14 | 269 | ||||||
| C. Thetford Smothers | 9 | 305 | 43 | 16 | 24 | 655 |
All Works
Loading papers...